Most Read Articles
Stephen Padilla, 6 days ago
Local clusters of the 2019 coronavirus disease (COVID-19) can be expected in countries with high travel volume from China before the lockdown of Wuhan and the institution of travel restrictions, according to a study in Singapore, wherein three initial clusters had been identified in February 2020: a tour group from China, a company conference, and a church.
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Product Highlight - Zavicefta

29 Nov 2019

Active ingredient: Ceftazidime (as pentahydrate) equivalent to 2 g and Avibactam (as sodium salt) equivalent to 0.5 g.

Indications: ZAVICEFTATM is indicated in adults for the treatment of the following infections

  • Complicated Intra-Abdominal Infection (cIAI)
  • Complicated Urinary Tract Infection, including Pyelonephritis (cUTI)
  • Hospital-acquired Pneumonia (HAP), including ventilator associated pneumonia (VAP)
  • Infections due to aerobic Gram-negative organisms in patients with limited treatment options
  • Consideration should be given to official guidance on the appropriate use of antibacterial agents. For treatment of cIAI use in combination with metronidazole.

Dosage & Administration: The recommended dosage of ZAVICEFTATM is 1 vial where each vial contains 2 g ceftazidime and 0.5 g avibactam administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes in patients aged 18 years or older. Treatment is repeated every 8 hours.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Thailand digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 6 days ago
Local clusters of the 2019 coronavirus disease (COVID-19) can be expected in countries with high travel volume from China before the lockdown of Wuhan and the institution of travel restrictions, according to a study in Singapore, wherein three initial clusters had been identified in February 2020: a tour group from China, a company conference, and a church.
Pearl Toh, 2 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
5 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.